Literature DB >> 16962955

Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins.

K Herzog-Tzarfati1, E Shiloah, M Koren-Michowitz, S Minha, M J Rapoport.   

Abstract

A 21-year-old previously healthy male presented with prolonged fever of 3 weeks duration and profound agranulocytosis that did not respond to treatment with granulocyte-stimulating factors. A bone marrow biopsy demonstrated an absence of myeloid lineage. Acute parvovirus B19 infection was diagnosed by the presence of both IgM and IgG anti-parvovirus antibodies. Two days treatment with intravenous immunoglobulins (IVIg) resulted in complete recovery. The role of treatment with immunoglobulins in acute and persistent parvovirus infection is discussed.

Entities:  

Year:  2006        PMID: 16962955     DOI: 10.1016/j.ejim.2006.02.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  4 in total

1.  Parvovirus B19 infection mimicking systemic lupus erythematosus, successfully treated with intravenous immune globulin.

Authors:  Sare Gülfem Özlü; Başak Alan; Aysegül Şahiner; Büşra Bulut; Gülsüm İclal Bayhan; Sonay İncesoy Özdemir
Journal:  Germs       Date:  2020-09-01

2.  Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.

Authors:  Ramon Diez-Feijóo; Juan Jose Rodríguez-Sevilla; Concepcion Fernández-Rodríguez; Solange Flores; Carmen Raya; Ana Ferrer; Luis Colomo; Antonio Salar
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

3.  Pure White Cell Aplasia and Necrotizing Myositis.

Authors:  Peter Geon Kim; Joome Suh; Max W Adelman; Kwadwo Oduro; Erik Williams; Andrew M Brunner; David J Kuter
Journal:  Case Rep Hematol       Date:  2016-03-17

Review 4.  Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis.

Authors:  C Giraud; Z Tatar; M Soubrier
Journal:  Clin Rheumatol       Date:  2016-08-19       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.